Equities
Health CareMedical Equipment and Services
  • Price (USD)68.49
  • Today's Change-0.13 / -0.19%
  • Shares traded6.53m
  • 1 Year change+40.93%
  • Beta0.7820
Data delayed at least 15 minutes, as of Mar 28 2024 20:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company’s segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. The Cardiovascular segment includes Cardiology and Peripheral Interventions. The Company's Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions.

  • Revenue in USD (TTM)14.24bn
  • Net income in USD1.57bn
  • Incorporated1979
  • Employees48.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BSX:NYQ since
announced
Transaction
value
Axonics IncAnnounced08 Jan 202408 Jan 2024Announced17.76%3.67bn
Relievant Medsystems IncDeal completed19 Sep 202319 Sep 2023Deal completed29.23%850.00m
Shockwave Medical IncRumoured21 Apr 202321 Apr 2023Rumoured30.16%--
Data delayed at least 15 minutes, as of Mar 28 2024 20:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
DexCom Inc3.62bn541.50m53.77bn9.60k108.8025.9973.9114.841.281.288.555.370.62153.044.29377,322.909.298.3013.1110.5063.6565.9014.9514.142.48--0.54650.0024.4928.5658.70--28.66--
Edwards Lifesciences Corp6.00bn1.40bn57.21bn19.80k41.348.6037.059.532.302.309.8511.060.68021.358.47303,272.7015.8516.6318.2119.1277.0276.7123.3024.842.40--0.08160.0011.5610.03-7.8513.701.96--
Becton Dickinson and Co19.49bn1.27bn71.22bn73.00k56.262.8120.083.654.384.2367.2587.680.36993.318.57267,013.702.472.372.892.7041.3745.786.686.950.64356.450.388781.232.663.92-4.8512.97-0.47373.94
Boston Scientific Corporation14.24bn1.57bn100.86bn48.00k64.075.2236.477.081.071.079.7313.160.42131.996.78296,666.704.712.505.432.9169.6568.8411.186.470.81705.160.31790.0012.297.71144.55-0.42767.82--
Medtronic PLC32.32bn4.20bn115.41bn95.00k27.562.2316.713.573.153.1524.2738.950.34952.005.45340,210.504.584.785.285.3765.7367.6813.1014.281.7130.780.326372.49-1.450.8366-25.42-6.956.448.13
Stryker Corp20.50bn3.17bn136.40bn52.00k43.497.3332.536.658.258.2553.4248.920.53381.675.59394,192.308.246.6010.127.8463.9063.9915.4413.130.9689--0.411443.7011.118.5534.229.680.104710.16
Intuitive Surgical, Inc.7.12bn1.80bn141.81bn13.68k79.5710.5962.4219.915.035.0319.9337.770.50142.276.88520,919.9012.7912.4214.4413.8366.3967.6025.5126.314.02--0.000.0014.4913.8535.989.7741.53--
Data as of Mar 28 2024. Currency figures normalised to Boston Scientific Corp's reporting currency: US Dollar USD

Institutional shareholders

39.08%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Dec 2023119.61m8.15%
The Vanguard Group, Inc.as of 31 Dec 2023119.28m8.13%
BlackRock Fund Advisorsas of 31 Dec 202367.86m4.63%
SSgA Funds Management, Inc.as of 31 Dec 202362.33m4.25%
Massachusetts Financial Services Co.as of 31 Dec 202357.18m3.90%
PRIMECAP Management Co.as of 31 Dec 202337.91m2.58%
Wellington Management Co. LLPas of 31 Dec 202336.44m2.48%
Geode Capital Management LLCas of 31 Dec 202327.56m1.88%
BlackRock Investment Management (UK) Ltd.as of 31 Dec 202322.74m1.55%
The Bollard Group LLCas of 31 Dec 202322.39m1.53%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.